(CRVO) CervoMed - Performance -60.8% in 12m
Compare CRVO with Indices, Sectors and Commodities and Bonds. Who performs better in which timeframe?
Performance Rating
-76.56%
#124 in Group
Rel. Strength
8.29%
#7328 in Universe
Total Return 12m
-60.80%
#121 in Group
Total Return 5y
-70.24%
#77 in Group
P/E -
(?) Percentile in Group
P/E Forward -
(?) Percentile in Group
PEG -
(?) Percentile in Group
FCF Yield -25.46%
52th Percentile in Group
12m Total Return: CRVO (-60.8%) vs XBI (-10.2%)

5y Drawdown (Underwater) Chart

Top Performers in Biotechnology
Overall best picks of Peer Group Selected by proven GARP Predictive Metrics, sorted by Growth Rating
Symbol | 1m | 12m | 5y | P/E | P/E Forward | PEG | EPS Stability |
EPS CAGR |
---|---|---|---|---|---|---|---|---|
ABBV NYSE AbbVie |
-18.6% | 9.15% | 153% | 75.1 | 14.6 | 0.38 | -49.6% | -19% |
UTHR NASDAQ United Therapeutics |
-11.8% | 21% | 168% | 11.8 | 10.6 | 1.43 | 83.8% | 78.5% |
HLN NYSE Haleon |
-0.87% | 26.7% | 40.5% | 24.7 | 20.3 | 1.8 | 27.1% | - |
AMGN NASDAQ Amgen |
-12.6% | 8.21% | 36.7% | 38.4 | 14.1 | 0.99 | -18.8% | -20% |
LONN SW Lonza |
-3.71% | 4.01% | 31% | 60.7 | 31.7 | 1.15 | 12.6% | -10.3% |
BIM PA Biomerieux |
-1.04% | 14.6% | 7.58% | 31.5 | 25.4 | 1.47 | -58.7% | -25.1% |
NBIX NASDAQ Neurocrine Biosciences |
-9.08% | -23.9% | -0.25% | 29.1 | 20.7 | 0.27 | 61.5% | 31.6% |
KMDA NASDAQ Kamada |
-4.41% | 31.6% | -2.82% | 24.3 | 22.8 | 0.91 | 47.7% | 3.93% |
Performance Comparison: CRVO vs XBI vs S&P 500
XBI (SPDR S&P Biotech ETF) is the Sector Benchmark for CRVO
Total Return (including Dividends) | CRVO | XBI | S&P 500 |
---|---|---|---|
1 Month | 8.29% | -13.99% | -6.90% |
3 Months | 364.45% | -13.68% | -11.64% |
12 Months | -60.80% | -10.17% | 6.50% |
5 Years | -70.24% | -19.71% | 101.06% |
Trend Score (consistency of price movement) | CRVO | XBI | S&P 500 |
1 Month | -22.9% | -80.4% | -74.5% |
3 Months | 72.7% | -89.8% | -88.2% |
12 Months | -87.6% | -26.1% | 66.1% |
5 Years | -74.0% | -52.8% | 84.3% |
Relative Strength (compared with Indexes) | Rank in Peer Group | vs. XBI | vs. S&P 500 |
1 Month | #20 | 25.9% | 16.3% |
3 Month | #1 | 438% | 426% |
12 Month | #121 | -56.4% | -63.2% |
5 Years | #80 | -62.9% | -85.2% |
FAQs
Does CRVO CervoMed outperforms the market?
No,
over the last 12 months CRVO made -60.80%, while its related Sector, the SPDR S&P Biotech (XBI) made -10.17%.
Over the last 3 months CRVO made 364.45%, while XBI made -13.68%.
Over the last 3 months CRVO made 364.45%, while XBI made -13.68%.
Performance Comparison CRVO vs Indeces and Sectors
CRVO vs. Indices CRVO is Over or Underperforming
Symbol | 1w | 1m | 6m | 12m | |
---|---|---|---|---|---|
US S&P 500 | SPY | 15.4% | 15.2% | -21.2% | -67.3% |
US NASDAQ 100 | QQQ | 16.2% | 16.2% | -20.9% | -65.7% |
US Dow Jones Industrial 30 | DIA | 16.7% | 14.7% | -21.5% | -66.2% |
German DAX 40 | DAX | 12.6% | 16.8% | -38.3% | -79.4% |
Shanghai Shenzhen CSI 300 | CSI 300 | 14.6% | 16.3% | -28.1% | -66.8% |
Hongkong Hang Seng | HSI | 11.5% | 19.0% | -24.7% | -77.7% |
India NIFTY 50 | INDA | 12.3% | 2.59% | -23.7% | -64.1% |
Brasil Bovespa | EWZ | 11.4% | 12.9% | -23.2% | -51.2% |
CRVO vs. Sectors CRVO is Over or Underperforming
Symbol | 1w | 1m | 6m | 12m | |
---|---|---|---|---|---|
Communication Services | XLC | 16.0% | 15.3% | -30.4% | -74.9% |
Consumer Discretionary | XLY | 17.0% | 13.9% | -24.0% | -69.3% |
Consumer Staples | XLP | 12.5% | 6.26% | -31.3% | -75.3% |
Energy | XLE | 9.83% | 18.2% | -21.6% | -50.2% |
Financial | XLF | 14.1% | 12.9% | -29.0% | -80.2% |
Health Care | XLV | 15.3% | 15.6% | -19.9% | -60.3% |
Industrial | XLI | 14.2% | 13.8% | -21.2% | -65.8% |
Materials | XLB | 12.4% | 15.1% | -14.1% | -53.3% |
Real Estate | XLRE | 10.3% | 11.8% | -22.9% | -77.9% |
Technology | XLK | 16.5% | 18.6% | -14.4% | -58.5% |
Utilities | XLU | 12.6% | 9.40% | -27.2% | -85.9% |
Aerospace & Defense | XAR | 13.4% | 8.93% | -30.7% | -85.0% |
Biotech | XBI | 9.67% | 22.3% | -6.72% | -50.6% |
Homebuilder | XHB | 15.1% | 15.7% | -3.66% | -51.6% |
Retail | XRT | 15.1% | 11.8% | -16.1% | -56.5% |